For decades, a deadly type of childhood cancer has eluded science’s best tools. Now doctors have made progress with an unusual treatment: Dripping millions of copies of a virus directly into kids’ brains to infect their tumors and spur an immune system attack.
A team of researchers at Fralin Biomedical Research Institute at VTC and City of Hope, a comprehensive care center, believes the complex way fluid flows through glioblastoma tumors holds the key to the therapy's success.
SynNotch-CAR T cell therapy is able to precisely target glioblastoma brain tumors.
For decades, a deadly type of childhood cancer has eluded science's best tools. Now doctors have made progress with an unusual treatment: dripping millions of copies of a virus directly into children's brains to infect their tumors and spur an immune system attack.
As a non-invasive treatment for select brain tumors and brain metastases, SRS is a well-studied and proven procedure that often provides equivalent or superior outcomes to surgery. Unlike surgery however, radiosurgery requires no incision and is painless.
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Cell Reports, offers an exciting new therapeutic approach for the treatment of DIPG by using a new anti-cancer drug. The new drug, CBL0137, is an anti-cancer compound developed from the antimalarial drug quinacrine.
Scientists at Sweden's Linköping University have developed a new tool to tackle these risky remnants of malignant tumors, demonstrating how an ion pump can take highly effective chemotherapy drugs directly to the source of the problem.
Scientists from Queen Mary University of London, funded by the charity Brain Tumour Research, have found a new way to starve cancerous brain tumour cells of energy in order to prevent further growth. The pre-clinical research in human tissue samples, human cell lines and mice could lead to changes in the way that some children with medulloblastoma are treated in the future.
Glioblastoma in rodents, and in human cells in a lab model, blocked by compound that researchers see as ‘paving the way for a new therapy’ for deadliest brain cancer Glioblastoma in rodents, and in human cells in a lab model, blocked by compound that researchers see as ‘paving the way for a new therapy’ for deadliest brain cancer.
A modified herpes virus, alone and in combination with radiation, has been shown to be well tolerated with early signs of clinical effectiveness in pediatric patients with high-grade brain tumors, or gliomas, according to findings from researchers at the University of Alabama at Birmingham and Children’s of Alabama.
Researchers at the University of Alabama at Birmingham have identified a potential pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer.
Now, new medical technology is offering what medical experts call a game changer. GammaTile therapy, a type of surgically targeted radiation therapy, is helping cancer patients to recover from brain tumor resection surgeries. GammaTile is a collagen tile that has a radiation source embedded in it. After a surgeon resects the tumor, the tile is placed inside the tumor bed, where it stays inside a person’s brain. It delivers radiation therapy from the moment it is inserted.
In a paper published in Scientific Reports last week, Yale researchers presented their development of a new sodium magnetic resonance spectroscopic imaging, or MRSI, method that will help detect gliomas, a type of brain tumor, in a non-invasive way.
The research, performed in animal models and human and mouse cells in culture, was published in the Journal of Clinical Investigation. The findings indicate that an adhesive cell surface protein known as N-cadherin — or N-cad — may be key in overcoming glioblastoma’s resistance to radiation therapy.
The Zika virus can activate immune cells to destroy an aggressive brain cancer in mice, giving a powerful boost to an immunotherapy drug and sparking long-lasting immunological memory that can ward off tumor recurrence for at least 18 months, according to a study posted on the website of Washington University School of Medicine in St. Louis on Wednesday. To better understand how Zika virus works against brain cancer, researchers at the university transplanted brain cancer cells into the brains of mice. One week later, they injected Zika virus into the mice's quickly growing tumors, or sterile saltwater for comparison.
Researchers and doctors from several centres across Germany, including the German Cancer Research Center, and the National Center for Tumor Diseases (NCT), carried out the first clinical trial to test a new vaccine against malignant brain tumours, according to a study published in the journal Nature (1). The results were very promising. Not only the vaccine was safe for all patients, but it also started the desired immune response in the cancerous tissue.
Physicians and cancer researchers in Heidelberg and Mannheim have for the first time carried out a clinical trial to test a cancer vaccine candidate that targets a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene. Results from the first-in-human Phase I study in glioma patients showed that repeated injections of the peptide vaccine were safe, and triggered the anticipated immune response in their tumor tissue.
There's a high probability that radio-frequency radiation from cellphones causes certain rare but often malignant brain tumors in humans, according to a former director of the National Center for Environmental Health at the Centers for Disease Control and Prevention. Dr. Christopher Portier submitted his findings as part of a lawsuit by patients and families against multiple cellphone manufacturers and carriers.
It has been reported that a new glioma-targeted nano-therapeutic that will only address tumor cells offering increased effectiveness and reduced side effects.
Brainstem glioma is often diagnosed in children and young adults and has a low survival rate. A multidisciplinary team at Washington University in St. Louis developed a technique that delivered a therapeutic agent to the gliomas using focused ultrasound with very promising results.
University Hospitals is using the Stealth Autoguide cranial robotic guidance platform, developed by Medtronic, to perform biopsies on brain cancer patients and other neurological procedures.
A simple blood test could reduce, or in some cases replace, the need for intrusive surgery when determining the best course of treatment for patients with a specific type of brain tumor, a new study finds. The researchers have discovered a biomarker, known as the protein Fibulin-2 (FBLN2), which helps to distinguish whether meningioma — the most common form of adult primary brain tumor — is a grade I or grade II.. Read more at: https://www.newsgram.com/study-simple-blood-test-can-treat-specific-type-of-brain-tumor/
Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.
A new study in Barcelona, Spain used personalized transcriptome sequencing to show that immune cells within the cerebrospinal fluid, particularly CD8 T-cells, faithfully model the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.
Shear wave elastography can outperform MRI in pinpointing whether any malignant tissue has been left behind after brain surgery. In a new study published in Frontiers in Oncology, a multi-institutional team discovered shear wave elastography was a much more sensitive technique.
A type of ultrasound scan can detect cancer tissue left behind after a brain tumor is removed more sensitively than surgeons, and could improve the outcome from operations, a new study suggests.
The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries and breakthroughs in oncology, especially those targeting glioblastoma.
“They drill a small hole in the bone or the skull,” Desjardins says. “It’s just above the tumor. Then, they put a small needle in.” It’s similar to a brain biopsy, but instead of taking a sample out, they put something in the brain. In this case, it was a bacterial toxin that attached to the receptors of the tumor cells.
New analysis of 3D images and quantitative data "will help to appreciate from within how the tumor is built in its full dimensionality, and to identify where different cell types are located", explains George Paul Cribaro, first author of the study. "It provides more complete information than the usual 2D analyses performed for neuropathological diagnosis".
A research team from both Scottish and UK institutions using infrared spectroscopy at Diamond Light Source reports a major advance in brain tumor diagnosis made by. This will enable non-invasive diagnoses of primary brain tumors (gliomas) and accelerate results as they will be available in real-time from a read out showing the kinds of mutations present in the gliomas of their patient.
Scientists from Korea and China have developed a multi-functional platform using gold nanostructures that allows growth of 3D spheroid cancer cells and their real-time monitoring under drug treatment in a non-invasive and repeatable fashion, crowning a novel approach to creating a realistic brain tumor model along with a rapid and precise method for anti-cancer drug screening.
A look at RNA tells us what our genes are telling our cells to do, and scientists say looking directly at the RNA of brain tumor cells appears to provide objective, efficient evidence to better classify a tumor and the most effective treatments.
Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in colon, endometrial, and other cancers. This alternative to complex, multi-step testing workflows can also determine causes of MMR deficiency often missed by current clinical tests.
A new combination of drugs could help to increase survival rates with fewer side effects for some children with one of the most aggressive forms of childhood brain cancer.
A look at RNA tells us what our genes are telling our cells to do, and scientists say looking directly at the RNA of brain tumor cells appears to provide objective, efficient evidence to better classify a tumor and the most effective treatments.
Researchers found that up to 20% of glioblastomas have overactive cellular power plants (mitochondria) and that their cells are relying on them for all their energy. This type of glioblastoma is associated with a slightly longer survival time, and its dependence on fuel generated by mitochondria may make it especially vulnerable to drugs that inhibit the structures.
A promising non-invasive treatment to effectively and safely destroy deadly brain tumors is being tested on human patients for the first time ever at the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix. This new treatment has shown to be incredibly effective in treating aggressive brain tumors in animals, said Dr. Shwetal Mehta, a molecular neuro-oncologist and the chief operating officer and deputy director of the center.
Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they’ve grown back, enabling up to 20% of patients to live well beyond predicted survival times.
Mitochondria are responsible for creating the energy that fuels all cells. Though they are usually less efficient at producing energy in cancer, tumor cells in this newly identified type of glioblastoma rely on the extra energy provided by overactive mitochondria to survive.
This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.
“Our research found that the CD200 protein was acting as a protective shield inside a person’s brain tumor, effectively preventing the immune system or immune-directed therapy from attacking the tumor,” said Dr. Olin. “The CD200 checkpoint inhibitor that we developed, along with a proven vaccine, has shown amazing results in our tests and has the potential to have fewer adverse effects for patients.”
“These patients appear to have a much more favorable prognosis and survive for years, if not decades. So, we decided to further investigate whether IDH mutations can predict which patients with low-grade glioma serve to benefit from the addition of chemotherapy to radiation vs. radiation alone.”
A powerful tool in The University of Kansas Health System’s surgical arsenal is the intraoperative MRI. We have an MRI scanner within the operating room, adjacent to the surgical table. Neurosurgeons begin the resection and remove as much of the tumor as we safely can. We then slide the patient on the surgical table directly into the MRI scanner to capture real-time images that may show us more tumor cells that can be removed during the same surgery.
Brain and spine surgeries can come down to mere millimeters in terms of being a success or a failure. At Virginia Brain and Spine Center (VBSC) in Winchester, which partners and works with Valley Health System, new technology is being used so neurosurgeons can perform procedures more efficiently and safely utilizing the Airo Mobile Intraoperative CT and the Curve Image Guided Surgery platform with neuronavigation technology.
Roswell Park Comprehensive Cancer Center has been working on multiple cancer research projects. One of these advancements is a drug called SurVaxM that was designed to treat a form of rare cancer called glioblastoma, will be used in a large clinical trial this year.
It was refreshing to hear about Gleolan, 5-aminolevulinic acid hydrochloride (5-ALA) powder for oral solution for marketing in Canada. It recently received a Notice of Compliance from Health Canada and is indicated in patients with glioma World Health Organization (WHO) Grades III or IV (suspected on preoperative imaging), as an adjunct for the visualization of malignant tissue during surgery.
Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now.
You must first understand how something works normally before you can figure out why it's broken. A researcher has now identified six mini gene co-expression networks for a normally functioning brain. That will allow researchers to test each of the gene teams to see if gene pairs are changing in brain tumors or people with intellectual disabilities.
Researchers at the Luxemburg Institute of Health Genes have identified the genes responsible for the extreme invasiveness of glioblastomas and the molecular regulator that switches them on.
The research team leveraged RNA interference -- a technique commonly used to uncover the function of a gene and its contribution to observed cellular characteristics -- to progressively silence and deactivate the entire set of genes of highly invasive patient-derived GBM cells and observe the consequences on the cell's ability to invade healthy tissues.
A Duke University spinout has developed an immune-boosting technology using variations of the polio vaccine that does more than wipe out a targeted solid tumor. “It clears the body of others as well, not just where it’s injected,” said Matt Stober, president and CEO of RTP-based Istari Oncology.
A new approach to cancer immunotherapy has the potential to be a universal treatment for solid tumors, according to researchers at Purdue University. Two Purdue scientists worked together to develop and test the new treatment that works not by attacking the cancer cells themselves, but by focusing on immune system cells that, ironically, feed the tumor and block other immune system cells from destroying it.
A study came out by Penn State College of Medicine suggests that a specific type of white blood cell can cause brain cancer tissues to die. This is good news. And the bad news is that a large number of these tissue deaths correspond to poor survival in patients with aggressive glioblastomas.
A study recently published in the journal Cancer Cell by VCU Massey Cancer Center scientist Suyun Huang, M.D., Ph.D., offers hope for the development of future therapies by showing how a poorly understood gene known as YTHDF3 plays a significant role in the process.
A study shows that different biological and treatment groups within the disease relapse at different times and with different patterns of spread throughout the body. Medulloblastoma is the most common malignant brain tumor in children and relapse following initial treatment has a grave prognosis, according to the authors.
Members of the Children's Brain Tumor Tissue Consortium and the Clinical Proteomic Tumor Analysis Consortium used proteogenomics to search for biological, biomarker, and therapeutic clues across several pediatric brain cancer types, uncovering tumors with possible treatment targets that clustered together proteomically across distinct histological tumor types.
Dr. Mark Hornyak, a Neurosurgeon with Hartford HealthCare’s Backus Hospital, explains more about the procedure.
Researchers at Newcastle University in the U.K. say that experts can identify the time, nature, and outcome of medulloblastoma relapse from the biology of the disease at diagnosis and the initial therapy received.
The researcher team found that the C11orf95 fragment primarily determines to which DNA segments the fusion protein binds. The RELA fragment then stabilizes the binding dynamic and drives the expression of ependymoma-associated genes.
To improve these odds and better match patients with the most appropriate drug protocol, researchers have developed a personalized drug screen that can be used to find the best drug candidate for a patient’s medulloblastoma type.
A new treatment approach for a deadly childhood brain tumor is undergoing trials in Seattle.
Breakthrough assay a ‘tenfold improvement over any prior assay for TERT mutations in the blood for brain tumors,’ MGH says in an affirmation of a diagnostic technology clinical labs might soon use
A new three-dimensional imaging technique has been developed that greatly improves the visibility of brain tumors in magnetic resonance imaging (MRI) scans. The technique, invented by a scientist at Northwestern University Feinberg School of Medicine, will potentially enable earlier diagnosis of tumors when they are smaller and more treatable.
A new three-dimensional imaging technique developed by researchers at Northwestern University Feinberg School of Medicine significantly improves the visibility of brain tumors in magnetic resonance imaging (MRI) scans, potentially enabling earlier diagnosis of tumors.
A study finds a new method of delivering radiation in a fraction of the time traditional therapies take can remove the debilitating after effects of killing tumors.
Scientists have discovered a way to stop the growth of glioblastoma, the deadliest form of brain cancer. The finding provides a new tactic in the war against cancer that involves reprogramming the immune system to do what it does best - fight the tumor instead of fueling it.
Adenocarcinoma in the brain is most often a cancer that has started in the lungs or the colon and spread. It is an aggressive, relentless disease. Now, a new form of treatment is providing increased quality of life for brain tumor patients.
A team of researchers at Massachusetts General Hospital have developed an enhanced form of liquid biopsy that that accurately detect and monitor mutations that promote the development of gliomas, the most common type of adult brain tumor.
An enhanced liquid biopsy test developed by researchers at Massachusetts General Hospital (MGH) has shown improved sensitivity for detecting specific biomarkers in gliomas that shows significant promising in both detecting and monitoring treatments for this deadly form of cancer.
It’s being called a major breakthrough in the fight against cancer. Researchers have developed a blood test that can detect brain tumors early, but that’s not the only thing this new test can do.
Genetic mutations that promote the growth of the most common type of adult brain tumors can be accurately detected and monitored in blood samples using an enhanced form of liquid biopsy developed by researchers at Harvard-affiliated Massachusetts General Hospital (MGH).
Cyberknife M6 is performed in a non-invasive manner with a higher brain surgery recovery time done on outpatient basis. The characteristics of M6 to pinpoint the exact location of the tumor in real time using 3-D imaging techniques during the treatment of brain tumor and ablating the tumor without any cut marks has proven outcomes to overtake the traditional methods of treatment.
A team led by University Hospital Zurich and the University of Zurich tested a protein-based drug that fuses immune-stimulating cytokines with antibodies that specifically target glioblastoma. The drug slowed tumor growth in mouse models of the disease and boosted the ability of immune cells to reach patients' brain tumors in a small, ongoing clinical trial.
This study found that the addition of immunotherapy to radiotherapy was associated with improved overall survival compared with radiotherapy alone in patients with brain metastases who received definitive surgery of the primary tumor site.
A team of scientists from Hokkaido University and Stanford University have revealed a mechanism by which GBM develops radioresistance. Their research, published in the journal Neuro-Oncology Advances, explains how two key molecules, Rab27b and epiregulin, interact to contribute to radioresistance in GBM.
"Advances in combination therapy have created new opportunities in cancer therapeutics, especially with regard to combatting drug resistance and tumor metastasis," said lead author of the study Jawad Fares, MD, Northwestern University.
In an interview with Targeted Oncology, David Roberge, MD, discussed the role of radiation treatment in patients with brain metastases and the clinical trial evaluating treatment approaches for patients with more than 5 brain metastases.
A research team at Korea University College of Medicine has confirmed the anticancer effects of psychoactive drugs in treating malignant brain tumors, suggesting a novel therapeutic approach. A malignant brain tumor is an intractable disease, which leads patients to death after only 12 to 14 months on average, even after receiving treatment. There is a high probability for patients to develop drug tolerance, one of the causes of short survival periods.
A roundup of several recent Michigan Medicine discoveries that are shedding new light on pediatric brain cancers and helping to improve treatment options. In honor of childhood cancer awareness month, here’s a look at a couple of recent research developments from Michigan Medicine.
Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38 for BMBC and rGBM, respectively, and produced partial responses in both cohorts of brain cancer patients.
Doctors at the Oklahoma Medical Research Foundation are celebrating what could become a breakthrough in brain cancer treatment. It's a drug that could become the only answer for those facing the devastating diagnosis. Researcher Dr. Rheal Towner has designed a medicine that fights DIPG, an uncurable form of pediatric brain cancer that effects around 300 children in the U.S. annually.
Using PET with the radiolabeled amino acid F-18 fluoroethyl-tyrosine (F-18-FET) can significantly help determine the efficacy of radiotherapy in certain cancer patients who develop brain metastases, according to a study in the Journal of Nuclear Medicine.
The medical device company NeuroOne Medical Technologies Corporation's new thin-film electrode technology, Evo Cortical, offers a potentially faster and less invasive diagnostic tool for identifying brain abnormalities in patients with epilepsy and brain tumors.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
McMaster University researchers have identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, the most serious form of pediatric brain cancer, making these aggressive forms of the disease more susceptible to therapy.
Brain cancer in children is always a devastating diagnosis, but McMaster University researchers may have found a way to have the most serious types of pediatric brain cancer respond better to therapies.
Research has identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, making these aggressive forms of cancer more responsive to therapies. The work also found the Wnt pathway, which has historically been considered cancer-promoting, to function as a cancer inhibitor in certain contexts.
Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy.
A new and sophisticated twist on the technology that brings us images of a fetus in utero will soon be used by physicians at Miami Neuroscience Institute and Miami Cancer Institute to treat some patients with movement disorders and brain tumors.
Glioblastomas are among the most aggressive brain tumors in adults and difficult to treat due to their rapid growth and their diversity. Usually, the malignant tumors cannot be completely or permanently removed by surgery. Thus, a combined radio- and chemotherapy follows, which, however, can be associated with side effects on the entire human body.
Radiotherapy changes the behavior of immune cells. In a study on mice, researchers were able to reprogram them to improve the effectiveness of treatment and, consequently, the survival rate.
A neurosurgeon at North Shore University Hospital has performed first-of-its-kind brain tumor surgery on Long Island using Synaptive’s Modus V™ 3D exoscope. The innovative technology is a fully automated, robotic digital microscope that combines advanced optics with 3D visualization, video processing and robotic automation allowing for a more precise excision of brain tumors.
In a study funded by the National Institutes of Health, researchers showed that experimental drugs designed to lower the body’s natural production of alpha-ketoglutarate extended the lives of mice harboring DIPG tumors by slowing the growth of the cancer cells. Interestingly, they also found that artificially raising alpha-ketoglutarate levels with DIPG-causing genes may slow the growth of other brain tumors
New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma. A McGill-led study published in Nature Communications reveals that suppressing the OSMR gene can improve the effectiveness of radiation therapy.
In the operating rooms at Southern New Hampshire Medical Center, surgeons have long offered robotic-assisted surgery using the da Vinci surgical system. The system is used for robotic-assisted minimally invasive procedures by cardiologists, colorectal surgeons, general surgeons, gynecological surgeons, head and neck surgeons, thoracic surgeons, and urologic surgeons. The existing system in Nashua is set to be upgraded, meaning patients will experience the most accurate, safe and successful robotic-assisted surgery available.
Findings, which appear in the journal Cancer Cell, suggest that simultaneously targeting two energy-production pathways within the cancer cells could help overcome the effects of a cancer-causing mutation that is one of the hallmarks of DIPG, or diffuse intrinsic pontine glioma, and similar tumors.
Specific genomic biomarkers can be used to identify glioma patients most likely to benefit from post-radiation chemotherapy and serve as a significant predictor of overall and progression-free survival, according to new data published by researchers at The Ohio State University Comprehensive Cancer Center.
Brain tumors are typically diagnosed using MRI imaging because taking a sample for a tissue biopsy is risky and may not be possible due to tumor location or a patient’s poor health conditions. Researchers at Washington University in St. Louis are developing a method to diagnose brain tumors without any incisions.
An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the future could perhaps also be used to treat diseases such as brain cancer, Alzheimer’s and Parkinson’s.
Much like the GPS technology that we use in cars and travelling, Neuro-navigation is a state-of-the-art technology that helps surgeons in a similar way to direct and guide them to the exact location of the tumor during surgery without causing any harm to the surrounding areas. This is achieved by feeding the patient’s preoperative Brain MRI or CT scan data into the software which are used as coordinates intraoperatively.
Glioblastoma, the most widespread and lethal primary brain tumor in adults, is notoriously difficult to treat due to the surrounding lack of oxygen essential to the effectiveness of current treatment. A team of CNRS and University of Caen Normandie researchers have successfully delivered the necessary oxygen to the tumor using zeolite nanocrystals.
A mouse model of glioblastoma suggests that this recalcitrant cancer originates from a pool of stem cells that can be a significant distance away from the resulting tumors. The findings of a new study, led by Children's National Hospital researchers and published July 22 in the journal Nature Communications, suggest new ways to fight this deadly disease.
Researchers affiliated with the University of Sao Paulo's Ribeirao Preto Medical School (FMRP-USP) in Brazil have demonstrated the potential of a leukemia drug, arsenic trioxide, to treat medulloblastoma, a type of brain cancer most common in children.
After discovering how a specific gene fuels a deadly form of children's brain tumor, University of Manitoba researchers have successfully decreased this cancer in mice.
Scientists at the University of Virginia School of Medicine have made a new discovery that could make all the difference in diagnosing the deadliest type of brain tumor. They’ve identified a gene that causes the deadliest brain tumor: glioblastoma.
The recently published study used cutting-edge methods, such as single cell sequencing, to conduct genome-wide analysis of individual tumor cells and to describe their molecular biological characteristics. The group found that ependymomas are very heterogeneous and consist of many cells with different characteristics, which complicates their treatment and might be the reason for chemotherapy resistance.
Working at the Australian Synchrotron facility in Melbourne, the scientists tested a technique for the treatment of high-grade brain cancer using personalized microbeam radiation therapy (MRT), combining it with an innovative assessment of tumor dose-coverage. MRT uses ultra-fine X-rays—each smaller in diameter than a human hair—to destroying the cancerous tissue while not harming the surrounding healthy tissue.
A Purdue University cancer innovator and his team have developed a promising new approach to treating these tumors using a type of immune cell called the natural killer (NK) cell. The team genetically modifies the NK cells to more specifically target and kill cancer cells.
As an ever-increasing number of complex surgeries are regularly being performed in an outpatient setting at ambulatory surgical centers, some brain tumor resections may be safe and feasible for appropriately selected patients, new research suggests.
Severance Hospital said it and two other institutions have jointly developed a biomarker and treatment for predicting the prognosis of glioblastoma, incurable cancer.
New findings suggest that maintaining high PAR levels (and low NAD+ levels), in combination with chemotherapy, may uniquely target IDH mutant glioma cells. Considering this, Hiroaki Nagashima, MD, PhD, research fellow and lead author, devised a new treatment strategy and tested it in tumor cells and animal models.
Gliomas with mutations in what are called the isocitrate dehydrogenase (IDH) genes are the most common brain tumors diagnosed in younger adults aged 18 to 45 years. Patients can benefit from aggressive surgery, along with radiation and chemotherapy treatments, but these therapies are not curative in many cases.
In a study published in eLife, researchers described the development of the Risk Assessment Population IDentification (RAPID) tool, an open-source machine learning algorithm. The tool revealed coordinated patterns of protein expression and modification associated with survival outcomes.
Israeli researchers have succeeded in destroying breast cancer cells after developing a new treatment that "combines the application of low-frequency ultrasound and microbubbles," Tel Aviv University's Department of Biomedical Engineering announced on Thursday. "Once the ultrasound is activated, the microbubbles attach themselves to cancer cells and explode like intelligent, targeted missiles, creating holes in the cell membrane and thus allowing the drug to be delivered."
Researchers at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) developed LIH383, a novel molecule that binds to and blocks a previously unknown opioid receptor in the brain, thereby modulating the levels of opioid peptides produced in the central nervous system (CNS) and potentiating their natural painkilling and antidepressant properties.
A noninvasive way to make a diagnosis of brain cancer would be a game-changer for both patients and healthcare practitioners, since access tumor tissue is not always possible. Another challenge in treating brain cancers is the accurate diagnosis of subtypes of brain cancers, information that is used to determine prognosis and assist in treatment planning.
A new blood test is promising a non-invasive way for clinicians to diagnose and classify brain tumors. The test will need further verification before it reaches clinical practice but it points to a novel way for doctors to detect brain cancer without the need for surgical tissue biopsies.
The University of Virginia School of Medicine is pioneering the use of focused ultrasound to kill cells associated with glioblastoma, a deadly brain tumor.T he technique uses a sonosensitizing drug to sensitize cancer cells to sound waves. The cancer cells are then hit with a focused ultrasound, which creates tiny bubbles inside the cancer cells to make them die.
Local researchers said they have developed a new nanotherapy that targets and treats a brain tumor. A joint research team of Professor Kim Do-kyoung at Kyung Hee University College of Medicine and Professor Kim Hyo-young at the Korea Institute of Science and Technology said on Thursday the novel nanotherapy could target glioblastoma, the most common brain cancer.
Researchers at Uppsala University have performed whole-genome sequencing to identify functional mutations and their effect on genes relevant to the development of glioblastoma (GBM).
Artificial Intelligence (AI) has enabled in pushing the boundaries of medical research. Proving that AI can help in better diagnosis and treatment of brain tumors, scientists have developed a new machine-learning algorithm that can classify tumors based on the severity.
Researchers from the Universities of Toronto and McMaster have just achieved promising results in trials of a new treatment for glioblastoma, a widespread and aggressive form of brain cancer.
One of our key tasks was to identify functional mutations associated with regulatory elements and potential relevance to the development of cancer cells, and to distinguish them from all random variations without presumed significance.
Endoscopic brain tumor surgery is minimally invasive treatment procedure that allows neurosurgeons to find and treat the conditions that are deep within the brain or access them through the nose. During this surgical method, thin tubing that transmits the video images of the brain is inserted through one or two small incisions in the skull or through an opening in the body.
NorthShore University HealthSystem (NorthShore) neurosurgeon, Julian Bailes, MD, is the first in Illinois to begin offering GammaTile® Therapy, a new approach to treating malignant brain tumors. The FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) is designed to delay tumor regrowth for patients with high grade gliomas, meningiomas and brain metastases.
Northwest Biotherapeutics, Inc. (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.
Oncologists hoping for more precise and individualized care for patients with brain cancers and metastases are continuing to research liquid biopsy technologies that could help them more easily and consistently analyze tumor genomics and monitor patients in ways that have so far been either difficult or impossible.
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin. The study captures in granular detail how the functions, locations and characteristics of various immune cells sculpt the tumor microenvironment (TME) to thwart immune attack, support cancer cell survival and drive tumor progression.
A team of researchers at the University of Zurich (UZH) and the University Hospital Zurich (USZ) has now found what types of immune cells are present in what numbers in different types of brain tumors. These very precise "tumor maps" are essential to gain a better understanding of the individual immune components in the tumor and to develop targeted immunotherapies that activate an immune defense reaction.
The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a new Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996. The study will evaluate central nervous system (CNS) penetration in patients with recurrent glioblastoma scheduled for resection. This is the first time a combination of these two drugs will be tested in brain tumor patients.
GBM is an aggressive form of cancer in the brain that is typically fatal. But new findings by VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) researchers could help increase the effectiveness of the most common current treatments with the addition of lumefantrine, an FDA-approved drug used to treat malaria.
"LITT stands for laser interstitial thermal therapy," says Dr. Scott Shepard, a neurosurgeon at Temple Health. The procedure uses a laser inserted into the brain through a tiny, pencil-sized hole to heat lesions or abnormalities.
Combining immunotherapy with tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice, according to new research out of Sanford Burnham Prebys.
Scientists at Sanford Burnham Prebys say they have discovered that combining immunotherapy with tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The findings also hold implications for other cancers that do not respond to immunotherapy.
Intel Labs and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) are co-developing a technology to enable a federation of 29 international healthcare and research institutions led by Penn Medicine to train artificial intelligence (AI) models that identify brain tumours using a privacy-preserving technique called federated learning.
Radiation is a key component of the standard-of-care treatment for the deadly brain cancer, glioblastoma; however, the treatment is rarely curative. While the growth of glioblastoma cells is often stalled by radiation, tumor growth inevitably resumes in nearly all treated patients.
project that will ultimately involve more than 15,000 patients in a first-time attempt to build a consensus model and help inform clinical decisions, Stat reports.
Research in cancer therapy is putting a lot of effort not only in the development of new drugs, but also in proposing new targeting strategies to selectively treat cancer cells. This would limit the dose of administered drugs as much as possible, decreasing the undesirable effects of chemotherapy, and, at the same time, increasing the efficacy of the treatment.
University of Virginia researchers are pioneering the use of focused ultrasound to defy the brain's protective barrier so that doctors could, at last, deliver many treatments directly into the brain to battle neurological diseases.
The approach, the researchers hope, could revolutionize treatment for conditions from Alzheimer's to epilepsy to brain tumors - and even help repair the devastating damage caused by stroke.
Focused ultrasound, the researchers hope, could revolutionize treatment for conditions from Alzheimer's to epilepsy to brain tumors -- and even help repair the devastating damage caused by stroke.
A team of researchers from the UCLA Jonsson Comprehensive Cancer Center has discovered that adding a drug more commonly used for schizophrenia alongside a radiation treatment helps to better treat glioblastoma, one of the deadliest and more aggressive brain tumors to treat.
Neurons and immune cells work together to promote tumor growth in neurofibromatosis type 1, research in mice suggests
The treatment, developed by TVAX Biomedical Inc., uses immunotherapy to treat glioblastoma, a type of malignant brain tumor. TVAX received a fast-track designation from the Food and Drug Administration, which allows the company to accelerate the approval process for the treatment and communicate more frequently with the FDA.
Promising new treatments for both primary and metastatic brain tumors, including gene therapy approaches, are constantly under development; however, brain neoplasms present tremendous challenges to effective therapeutic delivery.
A novel approach to treat medulloblastoma and ependymoma, researchers were able to deliver appropriately targeted chimeric antigen receptor (CAR) T cell therapy directly into the cerebrospinal fluid that surrounds the tumor.
The researchers report in the journal Nature Medicine that this approach was effective in treating these cancers in mouse models of human disease. The findings support further clinical studies to evaluate this strategy to treat pediatric brain cancers, the most common cause of cancer death in childhood.
Artificial intelligence may reduce the need for glioma brain cancer patients to have biopsies to determine the best treatment for their tumors, researchers report.
Currently, it's common to remove glioma samples from patients and analyze them to select appropriate therapy.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors.
Cancers whose cells are riddled with large numbers of DNA mutations often respond favorably to drugs called checkpoint blockers that unleash the immune system against the tumor. But a new study shows that malignant brain tumors known as gliomas generally don’t respond to the immunotherapy drugs.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors. The researchers found when the drug was given to mice 24 hours after the animals were exposed to a dose of radiation, it completely prevented cognitive decline from occurring, and that it did not reduce the efficacy of the radiation treatment.
The first sign of trouble for a patient with a growing brain tumor is often a seizure. Such seizures have long been considered a side effect of the tumor. But now a joint team of Columbia engineers and cancer researchers studying brain tumors has found evidence that the seizures caused by an enlarging tumor could spur its deadly progression.
Brain cancer in infants can be successful treated with targeted drugs, according to the findings published in Cancer Discovery. Babies and very young children, diagnosed when they are less than 12 months old, tend to have a better outcome – with around two thirds surviving five years or more.
The joint research team of Seoul National University Hospital (SNUH) and Massachusetts General Hospital (MGH) attached to Harvard University College of Medicine has recently released the results of analyzing the genetic mutations of metastatic brain tumors and primary lung cancer.
A team of researchers for Yale School of Medicine and Beijing Normal University just published a breakthrough study detailing a new method that offers a promise at treatment. The solution? Nanoparticles.
A group of researchers has devised a new way to study this rapidly spreading cancer, using a three-dimensional structure made of an agglomeration of human brain cells and biomaterials. Their work could help medical professionals better understand how the tumor grows and to speed up the potential discovery of new drugs to fight it.
Diverse Biotech, Inc. has announced it has signed an initial partnership agreement with The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center to study its potential new therapeutic candidates in glioblastoma. The research will be performed in animal models of the disease to evaluate the efficacy and tissue distribution of Diverse Biotech's new drug compounds.
To help doctors differentiate between the severity of cancers in the brain, an international team of researchers built a machine learning model that uses complex mathematics to learn how various types of brain tumors look in the brain.
In a recent study published in Autophagy, researchers at Kanazawa University show how abnormalities in a gene called TPR can lead to pediatric brain cancer.
The combined analysis of texture parameters of the CARS and TPEF signal proved to be most suited for the discrimination of non-tumor brain versus brain tumors (low and high grade astrocytoma, oligodendroglioma, glioblastoma, recurrent glioblastoma, brain metastases of lung, colon, renal and breast cancer and of malignant melanoma) leading to a correct rate of 96% (sensitivity: 96%, specificity: 100%).
Treatment for patients newly diagnosed with glioblastoma varies based on the size and location of the tumor, but historically it’s been comprised of surgery, radiation and chemotherapy. The new drug trial happening at UAB is focused on a different type of therapy, Drug Resistant Immunotherapy (DRI)
The University of Alabama at Birmingham (UAB) continues to evolve as a worldwide leader in biomedicine, research and innovation. A Birmingham-based biopharmaceutical company has now announced the initiation of a Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma. This trial is being conducted at UAB and is now active and open for enrollment.
In recent years, Johns Hopkins and several other academic medical centers around the world have been able to safely access tumors through brainstem safe entry zones. Yet, the benefits of aggressive resection have been unclear. Our study aimed to clarify the OS benefit among these patients.”
In research published in Science Advances, Xavier Intes, a professor of biomedical engineering at Rensselaer, joined a multidisciplinary team from Northeastern University and the Icahn School of Medicine at Mount Sinai to demonstrate a methodology that combines the bioprinting and imaging of glioblastoma cells in a cost-effective way that more closely models what happens inside the human body.
Venom, whether in snakes, scorpions or Gila monsters, are very complex chemicals. And in more than one instance, research into them has led to effective drugs.
Researchers with City of Hope have developed a chimeric antigen receptor (CAR) T cell therapy leveraging chlorotoxin (CLTX), a component of scorpion venom. In preclinical research published in Science Translational Medicine, they demonstrated that the therapeutics directed T cells to target brain tumor cells.
Researchers who discovered that an engineered cold sore virus could help destroy brain tumors from the inside out have determined a one-two punch might be the key to finish them off. This virotherapy could make a class of investigational cancer drugs more effective, according to investigators at The University of Texas Health Science Center at Houston (UTHealth).
University Hospitals is a part of a groundbreaking clinical study. It’s one of four places in the world that is working to slow the growth of malignant brain tumors, by injecting another disease in it.
MRI could help identify which patients with aggressive brain tumors might benefit from liquid biopsy, the blood test that pinpoints cancer DNA in a patient’s bloodstream. New research published today in Neuro-Oncology Advances shows that adding imaging to the mix when trying to diagnose and biopsy for glioblastoma (GBM) can help physicians determine which patients are good candidates for a liquid biopsy, as well as those who aren’t.
A new study will test a combined cancer vaccine which triggers immune responses against molecules that are expressed by GBM tumors. As it is a combined vaccine, it will target two molecules (TRP2 and WT1) which both play a significant role in GBM and are expressed in many GBM cells. It is expected that this study will provide a basis on which to move this new approach into the clinical setting.
GammaTile Therapy, marketed by GT Medical Technologies, became available to patients in January 2019 and is being used in top cancer treatment centers across the United States. It was initially approved for the treatment of recurrent brain tumors, including glioblastomas, gliomas, meningiomas, and brain metastases. The FDA expanded clearance of the technology in January to include treatment of newly diagnosed malignant brain tumors.
Scientists at the University of Pennsylvania have demonstrated that targeting a mechanism in a subset of stromal cells known as endothelial cells—which line the inside of blood vessels—might help overcome drug resistance in glioblastoma.
Yale researchers have found a way to weaponize structures from the Ebola virus in the fight against glioblastomas — ruthless brain tumors that are notoriously difficult to subdue.
Doctor has pushed the boundaries of innovation in her quest to increase the survival rates of individuals with brain tumors, especially glioblastomas. The esteemed physician-scientist has taken a truly comprehensive approach to battling this rare disease, which has a five year survival rate of only 10 percent and claimed the lives of U.S. Sens. Ted Kennedy and John McCain.
Researchers at the University of Virginia School of Medicine have determined that a rare childhood cancer, medulloblastoma, forms an unexpectedly intricate network to drive its growth. Some tumor cells actually turn into another type of cell altogether. The discovery raises the exciting possibility that doctors may be able to intervene to stop the disease – and possibly other cancers as well.
Radiation oncologists at the University of Louisville have for the first time in the U.S. treated a metastatic brain tumor with intraoperative radiation therapy supplied with the use of iCAD’s Xoft Axxent Electronic Brachytherapy System.
Glioblastomas are relentless, hard-to-treat, and often lethal brain tumors. Yale scientists have enlisted a most unlikely ally in efforts to treat this form of cancer — elements of the Ebola virus. The irony is that one of the world’s deadliest viruses may be useful in treating one of the deadliest of brain cancers,”
A study published in JAMA Oncology confirmed an association between maximal resection of contrast-enhanced tumor and overall survival (OS) in patients with glioblastoma across all subgroups.
Additionally, the researchers found that maximal resection of non-contrast-enhanced tumor was associated with longer OS in younger patients, regardless of isocitrate dehydrogenase (IDH) status, and among patients with IDH-wild-type glioblastoma regardless of the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase.
A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers. Yet a Mayo Clinic team and their collaborators took that counterintuitive approach and discovered that while it created resistance to chemotherapy, it also made tumors sensitive to immunotherapy.
Survival may more than double for adults with glioblastoma, the most common and deadly type of brain tumor, if neurosurgeons remove the surrounding tissue as aggressively as they remove the cancerous core of the tumor.
This discovery, reported in a retrospective study headed by researchers at UC San Francisco, is welcome news for those in the glioblastoma community, which celebrated its last breakthrough in 2005 with the introduction of the chemotherapy drug temozolomide.
Sam underwent DNA and RNA genomic sequencing at Mott to confirm which mutation was driving his cancer and help match him with an unconventional treatment to target that specific mutation. The sequencing results convinced doctors to treat the teen with a drug called everolimus – typically used to prevent rejection of organ transplants and in the treatment of renal cell cancer, not brain tumors.
Research in cell cultures and animal models suggests that scientists may be able to use a modified poliovirus to mount an immune response against brain tumor cells. Scientists know that the poliovirus is the pathogen that causes poliomyelitis, a disease that affects the central nervous system, potentially causing disability and, in the most severe cases, death.
Chinese researchers have developed robotic worms that can move through blood vessels to reach patients’ brains and directly destroy the tumors, avoiding the serious side effects of conventional treatments. According to an article in the South China Morning Post, researchers were able to create robotic worms that can travel through blood vessels to reach patients’ brains and target tumors directly.
Research in cell cultures and animal models suggests that scientists may be able to use a modified poliovirus to mount an immune response against brain tumor cells.
Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.
Scientists at Baylor College of Medicine have found new evidence that glioma, a lethal form of brain cancer, alters the activity of neighboring neurons, accelerating a vicious cycle that drives tumor-associated epilepsy and tumor progression. Their findings, published in Nature, showed that several variants of the PIK3CA gene drive tumor progression and that two variants in particular alter the expression of genes involved in synapses—junctions through which neurons communicate.
Researchers are at work to find effective treatments to help young patients with brain tumors. Hundreds of brain organoids have been developed in the laboratories of the University of Trento to understand the genetic mechanisms responsible for these hard-to-treat diseases.
Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.
The FDA has given the green light to an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to patients newly diagnosed with malignant brain tumors. About the size of a postage stamp, the bioresorbable GammaTile is designed to be placed within the brain after excision surgery, to deliver local doses of radiation at the site of any remaining cancer cells.
The Israeli-developed device, called the Optune helmet, said to prevent tumor growth using electric pulses, while causing minimal damage to healthy tissue. This FDA-approved treatment comes in the form of a device that delivers Tumor Treating Fields (TTFields) for glioblastoma (GBM), an aggressive form of brain cancer.
The first successful GammaTile procedure in North Carolina was recently performed at Vidant Medical Center.
Officials announced Thursday that the procedure, done along with East Carolina University's Brody School of Medicine, delays aggressive tumor regrowth for patients with brain tumors.
Cancer remains to be one of the medical research community's huge focuses and challenges, and scientists in Houston are continuing to innovate new treatments and technologies to make an impact on cancer and its ripple effect. Three research projects coming out of Houston institutions are providing solutions in the fight against cancer — from ways to monitor treatment to eliminating cancer-causing chemicals in the first place.
For select indications including many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) is proven to be an effective alternative to invasive surgery, thus potentially improving patient quality of life while significantly reducing the cost of care.
In a study led by Michigan Medicine, researchers combined laser imaging with artificial intelligence to help predict brain tumor diagnosis within minutes.
A new publication in Nature Medicine highlights how the NIO Imaging System from Invenio Imaging allows surgeons to get a real-time image of a piece of tissue from surgery and use artificial intelligence to get a rough diagnosis of the tissue’s composition.
A new study shows that children with medulloblastoma who were treated with radiotherapy had better intellectual outcomes when the radiation was delivered as proton beam therapy compared to traditional photon radiotherapy.
Researchers at NYU Grossman School of Medicine and the University of Michigan are proposing a new approach that may lead to more accurate brain tumor diagnoses by combining advanced optical imaging and artificial intelligence.
Johns Hopkins researchers report that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a "suicide gene" to pediatric brain tumor cells implanted in the brains of mice. The poly(beta-amino ester) nanoparticles, known as PBAEs, were part of a treatment that also used a drug to kill the cells and prolong the test animals' survival.
An optical imaging technique paired with an AI algorithm was able to analyze a tissue sample in less than 150 seconds, demonstrating how machine-learning can make a huge impact in the operating room. The AI was also able to detect some details conventional practices could miss. The new research comes as AI has recently proven to outperform humans in diagnosing breast and lung cancer.
In a paper published Monday in the journal Nature Medicine, researchers described an imaging technique called stimulated Raman histology, or SRH, that reveals tumor infiltration in human tissue by collecting scattered laser light to illuminate features not typically visible in standard histologic images.
Ground-breaking research by the University of Birmingham has discovered a new technique to assess the aggressiveness of childhood brain tumors. The study is the first of its kind and will allow clinicians to give more personalized treatments for childhood brain cancers, which currently account for one third of all childhood cancer deaths in the UK.
Glioblastoma is one of the most common and aggressive forms of brain cancer, and it is particularly difficult to treat. Now, researchers from the University of Pennsylvania School of Medicine have come up with a new approach to treatment for the disease, by growing organoids based on a patient’s own tumor to find the most effective treatments.
Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it. A new study in Cell from researchers at Penn Medicine showed how glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.